Novo petitions FDA over Victoza compounding as first generic wins approval

Novo Nordisk is continuing its citizen petition crusade at the FDA, this time aiming to stop the compounding of Victoza, its blockbuster GLP-1.

The push …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials – Biotech Investments

EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials 23.10.2023

October 24, 2023

Nuvectis launches Phase 1a dose escalation clinical trial of new cancer drug

Clinical trials have begun for a drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by US biopharmaceutical company Nuvectis Pharma,

September 15, 2023

First Drug OK’d for Chronic Rhinosinusitis With Nasal Polyps in Adolescents

The FDA broadened dupilumab’s (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals announced.

September 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.